VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH VENOUS THROMBOEMBOLISM

VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH VENOUS THROMBOEMBOLISM

Background: To assess the predictive validity of apixaban cost-effectiveness model by comparing key event rates from model to those seen in AMPLIFY and AMPLIFY-EXT trials in patients with venous thromboembolism (VTE).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2015-03, Vol.65 (10), p.A2087-A2087
Hauptverfasser: Lanitis, Tereza, Hamilton, Melissa, Rublee, Dale, Browne, Chantelle, Leipold, Robert, Quon, Peter, Masseria, Cristina, Cohen, Alexander
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Drug therapy
Heart attacks
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: To assess the predictive validity of apixaban cost-effectiveness model by comparing key event rates from model to those seen in AMPLIFY and AMPLIFY-EXT trials in patients with venous thromboembolism (VTE).
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(15)62087-3